Skip Ribbon Commands
Skip to main content


The challenge in advancing care and outcomes for childhood tumours lies in the coordination and provision of specialist care from multiple disciplines in order to provide holistic, comprehensive care to the child and the family. Patients with childhood tumours require prompt and efficient coordination of input and care from multiple disciplines at multiple points in their treatment. Here, the full spectrum of expertise and resources of a dedicated paediatric-specific cancer centre is critical for the successful care of patients with these complex conditions.

Current initiatives:

  1. SIOP Renal Tumour Study Group (RTSG) (UMBRELLA)

    SIOP RTSG UMBRELLA is a multicentre collaboration with the International Society of Paediatric Oncology – Renal Tumour Solid Group (SIOP RTSG)) to streamline and harmonise diagnostic and therapeutic procedures for all paediatric renal tumour patients internationally.

    The UMBRELLA protocol aims to validate new biomarkers (molecular, histopathological, and imaging) for the management of all children, adolescents and young adults with WT and other non-Wilms renal tumours of childhood. It aims to find new and better risk factors for treatment stratification and molecular targets for novel therapeutic approaches, with the ultimate goal of improving the short and long-term outcomes for all children with renal tumours.

    Patients on this protocol receive (i) centralised radiology and pathology review, and (ii) are assessed for copy number biomarkers that may have potential prognostic relevance in WT. This study is enrolling all children, adolescents or young adults with a primary or relapsed renal tumour.

  2. Paediatric Hepatic International Tumour Trial (PHITT)

    This Phase 2/3 trial is the first international cooperative liver tumours trial representing a consensus approach by the International Society of Paediatric Oncology Epithelial Liver Tumour (SIOPEL), the Liver Tumour Committee of the Children’s Oncology Group, USA (COG) and the Japan Children’s Cancer Group (JCCG). The multi-center trial aims to improve treatment and outcomes for children with liver cancer and uses a new unified international risk-adapted approach in treating children diagnosed with hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It also focuses on evaluating HB and HCC biology, as well as validating novel and reported prognostic and toxicity biomarkers. It is also designed to optimize the collection of clinically annotated biological specimens, thus establishing the world’s largest repository of blood and tissue samples from paediatric patients with HB and HCC.

  3. Multi-Tyrosine Kinase Receptor Inhibitor in Relapsed or Refractory Osteosarcoma

    This is a multi-center, sponsor-initiated Phase 2 trial with the primary objective of evaluating whether multi-tyrosine kinase receptor inhibitor in combination with chemotherapy, is superior to chemotherapy alone, in improving progression free survival rate at 4 months. This study is enrolling patients who are 2 years to 25 years of age who have a diagnosis of relapsed or refractory high-grade osteosarcoma and have received one or two prior lines of systemic therapy.

  4. Cancer Genetics

    In collaboration with the National Cancer Centre Singapore, we are studying cancer susceptibility and application of next generation clinical sequencing for patients with paediatric brain and solid tumours. Many familial cancer syndromes are associated with adult-onset and childhood-onset tumours. The identification and study of these children and their families has led to the discovery of many genes, all of which have pivotal roles in various stages of human tumorigenesis. Identification of tumour predisposition syndromes in patients who have cancer in childhood is paramount for optimal care.

  5. Advanced molecular diagnostics for paediatric brain and solid tumours

    Analysis of the genetic makeup of paediatric brain and solid tumours is essential to make rapid and accurate diagnoses so that the correct treatment can be administered. This is especially important in the current era of increasing molecular-based therapeutic approaches. A pathology consultation service is available for paediatric cancers including molecular pathology. Please email for instructions on referral arrangements.

For enquiries on trial participation, or other related questions, please contact us at